P53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour

Journal of Clinical Pathology

Volumn 67, Issue 3, 2014, Pages 235-242

  Yang, Yang ^a   Zhen, Tiantian ^a   Zhang, Fenfen ^a   Dai, Sujuan ^a   Kang, Lili ^a   Liang, Yingjie ^a   Xue, Ling ^a   Han, Anjia ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE TUMOUR PATHOLOGY; P53; SARCOMAS;

ADOLESCENT; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOMA, EWING; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894286738     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201705     Document Type: Article

References (31)

1. Krasin MJ, DavidoffAM, Rodriguez-Galindo C, et al. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. Cancer 2005;104:367-73. (Pubitemid 40993265)
2. Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73-83. (Pubitemid 37542320)
3. Bacci G, Ferrari S, Longhi A, et al. Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 2004;11:111-20.
4. Li Y, Li X, Fan G, et al. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 2012;320:14-22.
5. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-55. (Pubitemid 28175736)
6. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997;14:1159-64. (Pubitemid 27141917)
7. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245-51. (Pubitemid 26105532)
8. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-51. (Pubitemid 24188594)
9. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010;28:1982-8.
10. Ginsberg JP, de Alava E, Ladanyi M, et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999;17:1809-14. (Pubitemid 29269251)
11. Park YK, Chi SG, Kim YW, et al. P53 mutations in Ewing's sarcoma. Oncol Rep 2001;8:533-7.
12. Amir G, Issakov J, Meller I, et al. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum Pathol 2002;33:170-4. (Pubitemid 34298731)
13. Li Y, Tanaka K, Fan X, et al. Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. Cancer Lett 2010;294:57-65.
14. Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 2011;128:1139-50.
15. de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-92. (Pubitemid 30658577)
16. Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005;23:548-58. (Pubitemid 46224232)
17. Enomoto H, Yoshida K, Kishima Y, et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002;36:1519-27. (Pubitemid 35403542)
18. Everett AD, Lobe DR, Matsumura ME, et al. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000;105:567-75. (Pubitemid 30146503)
19. Lin YW, Li CF, Chen HY, et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol 2012;48:629-35.
20. Yoshida K, Tomita Y, Okuda Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006; 13:159-67. (Pubitemid 43157409)
21. Ren H, Tang X, Lee JJ, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004;22:3230-7. (Pubitemid 41103677)
22. Uyama H, Tomita Y, Nakamura H, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006;12:6043-8. (Pubitemid 44703767)
23. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006;12:117-22. (Pubitemid 43166184)
24. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 2007;14:2141-9. (Pubitemid 46988256)
25. Yang Y, Li H, Zhang F, et al. Clinical and biological significance of hepatomaderived growth factor in Ewing sarcoma. J Pathol 2013. [Epub ahead of print].
26. Sasaki Y, Negishi H, Idogawa M, et al. p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res 2011;71:7038-47.
27. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press, 2013.
28. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999;79:1185-9. (Pubitemid 29087896)
29. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-14.
30. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001;276:37564-8.
31. Savola S, Klami A, Tripathi A, et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009;9:17.